Nature Medicine
August 6, 2026
James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al.
1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
The Brown University Psychopharmacology Update
August 3, 2026
Individuals with cocaine use disorder who received a single dose of psilocybin combined with psychotherapy showed greater reductions in cocaine use relative to active placebo with psychotherapy, a randomized trial has found. No serious adverse events were reported during the trial.
British Journal of Mental Health Nursing
August 2, 2026
Rachel Sinclair
Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin...
Journal of Pain
August 1, 2026
Jon G Dean, Ethan Hurwitz, T. Furnish et al.
Phantom limb pain (PLP) is a refractory condition defined by pain experienced in a missing limb. Psilocybin, a classical serotonergic psychedelic drug, can alleviate various treatment-resistant disorders but has scantly been investigated for chronic pain. This placebo-controlled, double-blind, randomized clinical pilot trial (NCT05224336) tested the feasibility, tolerability, and preliminary...
Journal of Pain and Symptom Management
August 1, 2026
Daniel A. Schaefer, Manish Agrawal, Emanuele Mazzola et al.
CONTEXT Psilocybin-assisted therapy has demonstrated rapid antidepressant effects in patients with cancer, but most trials have excluded individuals receiving active systemic anticancer treatment, limiting safety data in this population. OBJECTIVES To compare the efficacy and safety of psilocybin-assisted therapy in patients receiving versus not receiving concurrent systemic anticancer...
European Journal of Pharmacology
August 1, 2026
Erik Kaadt, Rolf Søkilde, Hanne Demant Garling et al.
Novel treatment strategies are needed to address treatment resistance and delayed onset of action in psychiatry. Psilocybin has shown promise as a treatment for major depressive disorder, but the molecular changes associated with its effects remain incompletely understood. In parallel, microRNAs (miRNAs) have been implicated in depression and in responses to antidepressant interventions. Here,...
EBioMedicine
August 1, 2026
The use of psilocybin for treatment-resistant depression (TRD) is moving towards clinical use, and two unresolved questions will shape what comes next: how large and durable the benefit is, and what produces it? The strongest peer-reviewed efficacy signal is a phase 2b trial, in which one dose of synthetic psilocybin with psychological support approximately doubled the depression-score...
Journal of Affective Disorders
August 1, 2026
Taro Kishi, Kenji Sakuma, Masakazu Hatano et al.
This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups....
Journal of Affective Disorders
August 1, 2026
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al.
2 citations
The contribution of patient support to psilocybin's antidepressant effects remains uncertain. Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression...
Hearing research
August 1, 2026
Shuhan Lu, Zhixin Zhang, Xinmiao Xue et al.
Subjective tinnitus is a common auditory disorder characterised by the subjective perception of noise in the absence of external sound sources. Its prevalence has been rising annually due to noise exposure, medication misuse, and population ageing. Current tinnitus treatments employ antidepressants, anticonvulsants, and vasodilators, yet most demonstrate limited efficacy with significant side...